
    
      PRIMARY OBJECTIVES:

      I. To perform blood-based genomic profiling on patients with treatment refractory metastatic
      colorectal cancer (CRC) to facilitate accrual to molecularly assigned therapies.

      II. To facilitate clinically annotated genomic analyses.

      OUTLINE:

      Patients submit blood samples for genetic testing.
    
  